The reiteration of a Buy rating and maintenance of a $171 price target by a reputable analyst firm like Canaccord Genuity is likely to instill confidence among investors and could positively influence BioNTech's stock price in the short term. The specific mention of the price target provides a clear benchmark for expectations.